# Vutrisiran

Drug · id `cardio:vutrisiran` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

Also called: Amvuttra; Vutrisiran sodium

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

Vutrisiran is the medicine in Amvuttra, a solution for injection under the skin. The US label calls it a transthyretin-directed small interfering RNA, and says it causes degradation of the messenger RNA for transthyretin (TTR) through RNA interference, which reduces TTR protein and its deposits in tissues. The label lists two indications in adults: the polyneuropathy of hereditary transthyretin-mediated amyloidosis, and the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis, to reduce cardiovascular mortality, cardiovascular hospitalizations and urgent heart failure visits. The atlas holds no trial results for it.

## Technical summary

RxNorm ingredient 2604578 (vutrisiran); the label names the salt vutrisiran sodium, whose UNII 28O0WP6Z1P is a broad match to the ingredient. RxClass lists the FDA established pharmacologic classes Small Interfering RNA and Transthyretin-directed RNA Interaction, so the record is filed under the class page on the second. MeSH has no descriptor for vutrisiran (an exact-label lookup returned an empty list on 2026-11-19). The label read is the Alnylam Pharmaceuticals, Inc. label for Amvuttra, application NDA215515, effective 2025-11-06 in openFDA; it is the only openFDA label returned for the ingredient, and Drugs@FDA lists one application with one product. The record read has no boxed warning section. This page records the label indications, the class and the mechanism sentence only: no trial result and no dose is given.

## Claims, with the population each applies to

## Context: Adults with the polyneuropathy of hereditary transthyretin-mediated amyloidosis, or with the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis, as described in the US label of Amvuttra

Recipient: Recipient not specified; Population: Adults in the two groups the indications section of the label names: adults with the polyneuropathy of hereditary transthyretin-mediated amyloidosis, and adults with the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis. The passages read give no other age range.; Care setting: Prescription medicine, as described in the US label; Geography: United States (label of the US Food and Drug Administration); Life stage: Not stated in the label passages read; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (label statement)

### The US label of Amvuttra (vutrisiran injection; Alnylam Pharmaceuticals, Inc., application NDA215515; the version dated 2025-11-06 in openFDA) calls the product a transthyretin-directed small interfering RNA. It lists two indications in adults: the polyneuropathy of hereditary transthyretin-mediated amyloidosis, and the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis, to reduce cardiovascular mortality, cardiovascular hospitalizations and urgent heart failure visits.

- Category: Description
- Evidence stage: Evidence stage not applicable
- Certainty: Certainty not assessed
- Applies to: Recipient: Recipient not specified; Population: Adults in the two groups the indications section of the label names: adults with the polyneuropathy of hereditary transthyretin-mediated amyloidosis, and adults with the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis. The passages read give no other age range.; Care setting: Prescription medicine, as described in the US label; Geography: United States (label of the US Food and Drug Administration); Life stage: Not stated in the label passages read; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (label statement)
- Limitations: This claim records what one US label says the medicine is indicated for. It is not a finding about how well the medicine works, and the atlas holds no trial result for it. The polyneuropathy indication concerns the nerves, not the heart, and the atlas gives it no page of its own. The label read has no boxed warning section. Contraindications, other warnings, interactions, the pregnancy, lactation and pediatric sections and dosing were not recorded. Labels change, and openFDA's own disclaimer says not to rely on it for decisions about medical care.
- Last checked: 2026-11-19
- Sources:
  1. Background: openFDA drug label record for vutrisiran injection (Amvuttra), Alnylam Pharmaceuticals, Inc. label: indications, mechanism, class wording (Regulator, edition The openFDA drug label record for set id 8db0facb-81b6-4006-9239-27dc6409c5d3 (manufacturer Alnylam Pharmaceuticals, Inc., application NDA215515), returned on 2026-11-19. The label text is dated 2025-11-06 (effective\_time). It is the only openFDA label record for this ingredient returned by an openFDA generic-name search on 2026-11-19.) <https://api.fda.gov/drug/label.json?search=set_id:%228db0facb-81b6-4006-9239-27dc6409c5d3%22&limit=1>
     Locator: results\[0\].openfda.application\_number\[0\]. Retrieved 2026-11-19T00:29:53Z. Source state: Current. Version fingerprint: 4c2b6cc7b3436519280363a727220ae794f635cb4356c3bb10abf8e1c74079aa.
     How it applies: Application number of the label read, NDA215515.
  2. Background: openFDA drug label record for vutrisiran injection (Amvuttra), Alnylam Pharmaceuticals, Inc. label: indications, mechanism, class wording (Regulator, edition The openFDA drug label record for set id 8db0facb-81b6-4006-9239-27dc6409c5d3 (manufacturer Alnylam Pharmaceuticals, Inc., application NDA215515), returned on 2026-11-19. The label text is dated 2025-11-06 (effective\_time). It is the only openFDA label record for this ingredient returned by an openFDA generic-name search on 2026-11-19.) <https://api.fda.gov/drug/label.json?search=set_id:%228db0facb-81b6-4006-9239-27dc6409c5d3%22&limit=1>
     Locator: results\[0\].effective\_time. Retrieved 2026-11-19T00:29:53Z. Source state: Current. Version fingerprint: 4c2b6cc7b3436519280363a727220ae794f635cb4356c3bb10abf8e1c74079aa.
     How it applies: Effective date of the label text read, 20251106.
  3. Supports: openFDA drug label record for vutrisiran injection (Amvuttra), Alnylam Pharmaceuticals, Inc. label: indications, mechanism, class wording (Regulator, edition The openFDA drug label record for set id 8db0facb-81b6-4006-9239-27dc6409c5d3 (manufacturer Alnylam Pharmaceuticals, Inc., application NDA215515), returned on 2026-11-19. The label text is dated 2025-11-06 (effective\_time). It is the only openFDA label record for this ingredient returned by an openFDA generic-name search on 2026-11-19.) <https://api.fda.gov/drug/label.json?search=set_id:%228db0facb-81b6-4006-9239-27dc6409c5d3%22&limit=1>
     Locator: results\[0\].indications\_and\_usage\[0\], highlights sentence. Retrieved 2026-11-19T00:29:53Z. Source state: Current. Version fingerprint: 4c2b6cc7b3436519280363a727220ae794f635cb4356c3bb10abf8e1c74079aa.
     How it applies: Label passage quoted in the research quote table (Q-W4K28-VUT-LB-04).
  4. Supports: openFDA drug label record for vutrisiran injection (Amvuttra), Alnylam Pharmaceuticals, Inc. label: indications, mechanism, class wording (Regulator, edition The openFDA drug label record for set id 8db0facb-81b6-4006-9239-27dc6409c5d3 (manufacturer Alnylam Pharmaceuticals, Inc., application NDA215515), returned on 2026-11-19. The label text is dated 2025-11-06 (effective\_time). It is the only openFDA label record for this ingredient returned by an openFDA generic-name search on 2026-11-19.) <https://api.fda.gov/drug/label.json?search=set_id:%228db0facb-81b6-4006-9239-27dc6409c5d3%22&limit=1>
     Locator: results\[0\].indications\_and\_usage\[0\], section 1.2. Retrieved 2026-11-19T00:29:53Z. Source state: Current. Version fingerprint: 4c2b6cc7b3436519280363a727220ae794f635cb4356c3bb10abf8e1c74079aa.
     How it applies: Label passage quoted in the research quote table (Q-W4K28-VUT-LB-05).
  5. Supports: openFDA drug label record for vutrisiran injection (Amvuttra), Alnylam Pharmaceuticals, Inc. label: indications, mechanism, class wording (Regulator, edition The openFDA drug label record for set id 8db0facb-81b6-4006-9239-27dc6409c5d3 (manufacturer Alnylam Pharmaceuticals, Inc., application NDA215515), returned on 2026-11-19. The label text is dated 2025-11-06 (effective\_time). It is the only openFDA label record for this ingredient returned by an openFDA generic-name search on 2026-11-19.) <https://api.fda.gov/drug/label.json?search=set_id:%228db0facb-81b6-4006-9239-27dc6409c5d3%22&limit=1>
     Locator: results\[0\].indications\_and\_usage\[0\], section 1.1. Retrieved 2026-11-19T00:29:53Z. Source state: Current. Version fingerprint: 4c2b6cc7b3436519280363a727220ae794f635cb4356c3bb10abf8e1c74079aa.
     How it applies: Label passage quoted in the research quote table (Q-W4K28-VUT-LB-06).

## Connected pages

- Vutrisiran is a transthyretin-directed RNA interaction drug, a small interfering RNA (FDA established pharmacologic classes in RxClass): Transthyretin stabilizers and transthyretin-directed RNA interaction medicines (`cardio:transthyretin-directed-medicines`)
- FDA label lists the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis in adults, to reduce cardiovascular mortality, cardiovascular hospitalizations and urgent heart failure visits, as an indication: Cardiac amyloidosis (`cardio:cardiac-amyloidosis`) [a claim, not a settled fact; see claim `cardio:claim-fda-amvuttra-label-indications` and its context]
- Both are small interfering RNA medicines, but inclisiran acts on PCSK9 to lower LDL cholesterol and vutrisiran acts on transthyretin: Inclisiran (`cardio:inclisiran`)
- Files under this front: Medicines (`cardio:front-medicines`)

## Provenance

Content hash: ac42f7425d7305845a0d90f50c84e34d55a513a3b095867d83d88057d404bc23
Last substantive edit: 2026-11-19
Evidence last checked: 2026-11-19
